Shanghai Haohai Biological Technology Co., Ltd.
Simbol: 6826.HK
HKSE
42.45
HKDTržna cena danes
15.1027
Razmerje P/E
0.7575
Razmerje PEG
16.43B
Kapaciteta MRK
- 0.01%
Donos DIV
Shanghai Haohai Biological Technology Co., Ltd. (6826-HK) Finančni izkazi
Bilanca stanja
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 2751.1 | 2541.7 | 2907.2 | ||||||||||
balance-sheet.row.short-term-investments | 0 | 11.1 | 6.7 | 6.4 | ||||||||||
balance-sheet.row.net-receivables | 0 | 447.6 | 471.1 | 375.2 | ||||||||||
balance-sheet.row.inventory | 0 | 526.2 | 485.2 | 354.8 | ||||||||||
balance-sheet.row.other-current-assets | 0 | 25.2 | 34.1 | 69.6 | ||||||||||
balance-sheet.row.total-current-assets | 0 | 3750.1 | 3532.1 | 3712.6 | ||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 1553 | 1409.6 | 1248.9 | ||||||||||
balance-sheet.row.goodwill | 0 | 413 | 411.2 | 406.9 | ||||||||||
balance-sheet.row.intangible-assets | 0 | 729.1 | 783.5 | 783.1 | ||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 1142.1 | 1194.7 | 1190 | ||||||||||
balance-sheet.row.long-term-investments | 0 | 596 | 664.7 | 619 | ||||||||||
balance-sheet.row.tax-assets | 0 | 53.1 | 59.3 | 49.4 | ||||||||||
balance-sheet.row.other-non-current-assets | 0 | 11.1 | 32 | 130.5 | ||||||||||
balance-sheet.row.total-non-current-assets | 0 | 3355.4 | 3360.3 | 3237.8 | ||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-assets | 0 | 7105.5 | 6892.4 | 6950.4 | ||||||||||
balance-sheet.row.account-payables | 0 | 55.1 | 54.5 | 46.3 | ||||||||||
balance-sheet.row.short-term-debt | 0 | 216.6 | 34.4 | 66 | ||||||||||
balance-sheet.row.tax-payables | 0 | 58.4 | 52.1 | 17.8 | ||||||||||
balance-sheet.row.long-term-debt-total | 0 | 191.3 | 83.9 | 39.5 | ||||||||||
Deferred Revenue Non Current | 0 | 13.6 | 5.5 | 9.4 | ||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||
balance-sheet.row.other-current-liab | 0 | 444.2 | 422.4 | 375 | ||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 372.3 | 478.7 | 402.8 | ||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 54.2 | 61.3 | 46.7 | ||||||||||
balance-sheet.row.total-liab | 0 | 1088.2 | 990 | 890.1 | ||||||||||
balance-sheet.row.preferred-stock | 0 | 71.7 | 47 | 0 | ||||||||||
balance-sheet.row.common-stock | 0 | 171.5 | 174.1 | 175.8 | ||||||||||
balance-sheet.row.retained-earnings | 0 | 2728.6 | 2369.5 | 2309.7 | ||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -71.7 | -47 | 47.9 | ||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 2750 | 2971 | 3180 | ||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 5650.1 | 5514.6 | 5713.5 | ||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 7105.5 | 6892.4 | 6950.4 | ||||||||||
balance-sheet.row.minority-interest | 0 | 367.2 | 387.8 | 346.8 | ||||||||||
balance-sheet.row.total-equity | 0 | 6017.3 | 5902.4 | 6060.3 | ||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||
Total Investments | 0 | 607.1 | 671.4 | 625.3 | ||||||||||
balance-sheet.row.total-debt | 0 | 407.9 | 118.3 | 105.5 | ||||||||||
balance-sheet.row.net-debt | 0 | -2332.1 | -2423.5 | -2795.3 |
Izkaz denarnih tokov
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 508.3 | 235.7 | 382.6 | ||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 197.9 | 204.2 | 162.8 | ||||||||||
cash-flows.row.deferred-income-tax | 0 | -81.6 | 0 | 0 | ||||||||||
cash-flows.row.stock-based-compensation | 0 | 14.3 | 30.2 | 0 | ||||||||||
cash-flows.row.change-in-working-capital | 0 | 73.2 | -183.5 | 23.9 | ||||||||||
cash-flows.row.account-receivables | 0 | 0 | -52.3 | -41.9 | ||||||||||
cash-flows.row.inventory | 0 | -48.4 | -138.9 | -28.6 | ||||||||||
cash-flows.row.account-payables | 0 | 0 | 52.3 | 41.9 | ||||||||||
cash-flows.row.other-working-capital | 0 | 121.6 | -44.6 | 52.6 | ||||||||||
cash-flows.row.other-non-cash-items | 0 | -77.6 | -55.4 | -227.1 | ||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -267.2 | -317.1 | -272.1 | ||||||||||
cash-flows.row.acquisitions-net | 0 | 1.6 | 14.7 | -83.3 | ||||||||||
cash-flows.row.purchases-of-investments | 0 | -204.2 | -528.8 | -696.6 | ||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 14.6 | 9.1 | 749.3 | ||||||||||
cash-flows.row.other-investing-activites | 0 | 78.6 | 140.4 | 154.6 | ||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -376.6 | -681.8 | -148.1 | ||||||||||
cash-flows.row.debt-repayment | 0 | -16.4 | -47.9 | -95.5 | ||||||||||
cash-flows.row.common-stock-issued | 0 | 73.7 | 0 | -4 | ||||||||||
cash-flows.row.common-stock-repurchased | 0 | -270 | -147.7 | -44.9 | ||||||||||
cash-flows.row.dividends-paid | 0 | -68.5 | -121.9 | -87.9 | ||||||||||
cash-flows.row.other-financing-activites | 0 | -245.7 | 29.1 | 1.1 | ||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -257.7 | -288.4 | -231.3 | ||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 10 | 14.2 | -6.9 | ||||||||||
cash-flows.row.net-change-in-cash | 0 | 10.1 | -724.7 | -44 | ||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 569.3 | 559.2 | 1283.9 | ||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 559.2 | 1283.9 | 1327.9 | ||||||||||
cash-flows.row.operating-cash-flow | 0 | 634.5 | 231.3 | 342.3 | ||||||||||
cash-flows.row.capital-expenditure | 0 | -267.2 | -317.1 | -272.1 | ||||||||||
cash-flows.row.free-cash-flow | 0 | 367.2 | -85.9 | 70.2 |
Vrstica izkaza poslovnega izida
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 2634.9 | 2103.4 | 1750.1 | ||||||||||
income-statement-row.row.cost-of-revenue | 0 | 781.4 | 656.5 | 490.4 | ||||||||||
income-statement-row.row.gross-profit | 0 | 1853.5 | 1446.9 | 1259.7 | ||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.other-expenses | 0 | -4 | -40.3 | -33.9 | ||||||||||
income-statement-row.row.operating-expenses | 0 | 1415.1 | 1226.8 | 1032.2 | ||||||||||
income-statement-row.row.cost-and-expenses | 0 | 2196.5 | 1883.3 | 1522.5 | ||||||||||
income-statement-row.row.interest-income | 0 | 77.7 | 87.9 | 98.2 | ||||||||||
income-statement-row.row.interest-expense | 0 | 7.3 | 7.6 | 5 | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -4.7 | -22.9 | -1.8 | ||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.other-operating-expenses | 0 | -4 | -40.3 | -33.9 | ||||||||||
income-statement-row.row.total-operating-expenses | 0 | -4.7 | -22.9 | -1.8 | ||||||||||
income-statement-row.row.interest-expense | 0 | 7.3 | 7.6 | 5 | ||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 197.9 | 204.2 | 162.8 | ||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.operating-income | 0 | 513 | 258.7 | 384.4 | ||||||||||
income-statement-row.row.income-before-tax | 0 | 508.3 | 235.7 | 382.6 | ||||||||||
income-statement-row.row.income-tax-expense | 0 | 96 | 45.4 | 35.4 | ||||||||||
income-statement-row.row.net-income | 0 | 416.1 | 180.5 | 352.2 |
Pogosto zastavljeno vprašanje
Kaj je Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) skupna sredstva?
Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) skupna sredstva so 7105497000.000.
Kakšen je letni prihodek podjetja?
Letni prihodki so N/A.
Kolikšna je stopnja dobička podjetja?
Dobiček podjetja je 0.698.
Kakšen je prosti denarni tok podjetja?
Prosti denarni tok je 1.049.
Kolikšna je neto stopnja dobička podjetja?
Čista stopnja dobička je 0.162.
Kolikšni so skupni prihodki podjetja?
Celotni prihodki so 0.177.
Kaj je Shanghai Haohai Biological Technology Co., Ltd. (6826.HK) čisti dobiček (čisti dobiček)?
Čisti dobiček (čisti prihodek) je 416121000.000.
Kolikšen je skupni dolg podjetja?
Skupni dolg je 407949000.000.
Kolikšni so stroški poslovanja?
Stroški poslovanja so 1415132000.000.
Kolikšno je število denarnih sredstev podjetja?
Denarna sredstva podjetja so 0.000.